BEVACIZUMAB, IRINOTECAN, TEMOZOLOMIDE, TYROSINE KINASE INHIBITION, AND MEK INHIBITION ARE EFFECTIVE AGAINST PLEOMORPHIC XANTHOASTROCYTOMA REGARDLESS OF V600E STATUS
Publication
, Conference
Thompson, E; Landi, D; Ashley, D; Keir, S; Bigner, D
Published in: NEURO-ONCOLOGY
November 1, 2018
Duke Scholars
Published In
NEURO-ONCOLOGY
EISSN
1523-5866
ISSN
1522-8517
Publication Date
November 1, 2018
Volume
20
Start / End Page
102 / 102
Location
New Orleans, LA
Publisher
OXFORD UNIV PRESS INC
Conference Name
23rd Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO) / 3rd CNS Anticancer Drug Discovery and Development Conference
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Thompson, E., Landi, D., Ashley, D., Keir, S., & Bigner, D. (2018). BEVACIZUMAB, IRINOTECAN, TEMOZOLOMIDE, TYROSINE KINASE INHIBITION, AND MEK INHIBITION ARE EFFECTIVE AGAINST PLEOMORPHIC XANTHOASTROCYTOMA REGARDLESS OF V600E STATUS. In NEURO-ONCOLOGY (Vol. 20, pp. 102–102). New Orleans, LA: OXFORD UNIV PRESS INC.
Thompson, Eric, Daniel Landi, David Ashley, Steve Keir, and Darell Bigner. “BEVACIZUMAB, IRINOTECAN, TEMOZOLOMIDE, TYROSINE KINASE INHIBITION, AND MEK INHIBITION ARE EFFECTIVE AGAINST PLEOMORPHIC XANTHOASTROCYTOMA REGARDLESS OF V600E STATUS.” In NEURO-ONCOLOGY, 20:102–102. OXFORD UNIV PRESS INC, 2018.
Thompson E, Landi D, Ashley D, Keir S, Bigner D. BEVACIZUMAB, IRINOTECAN, TEMOZOLOMIDE, TYROSINE KINASE INHIBITION, AND MEK INHIBITION ARE EFFECTIVE AGAINST PLEOMORPHIC XANTHOASTROCYTOMA REGARDLESS OF V600E STATUS. In: NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2018. p. 102–102.
Thompson, Eric, et al. “BEVACIZUMAB, IRINOTECAN, TEMOZOLOMIDE, TYROSINE KINASE INHIBITION, AND MEK INHIBITION ARE EFFECTIVE AGAINST PLEOMORPHIC XANTHOASTROCYTOMA REGARDLESS OF V600E STATUS.” NEURO-ONCOLOGY, vol. 20, OXFORD UNIV PRESS INC, 2018, pp. 102–102.
Thompson E, Landi D, Ashley D, Keir S, Bigner D. BEVACIZUMAB, IRINOTECAN, TEMOZOLOMIDE, TYROSINE KINASE INHIBITION, AND MEK INHIBITION ARE EFFECTIVE AGAINST PLEOMORPHIC XANTHOASTROCYTOMA REGARDLESS OF V600E STATUS. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2018. p. 102–102.
Published In
NEURO-ONCOLOGY
EISSN
1523-5866
ISSN
1522-8517
Publication Date
November 1, 2018
Volume
20
Start / End Page
102 / 102
Location
New Orleans, LA
Publisher
OXFORD UNIV PRESS INC
Conference Name
23rd Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO) / 3rd CNS Anticancer Drug Discovery and Development Conference
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences